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Cutting Edge: Competition for APC by CTLs of
Different Specificities Is Not Functionally Important
During Induction of Antiviral Responses1
Hans Christian Probst,2 Tilman Dumrese,2 and
Maries F. van den Broek3
The hypothesis that T cell competition for access to APC in-
fluences priming of CTL responses is a controversial issue. A
recent study using OVA as a model Ag supports this hypoth-
esis and received considerable attention. However, using a
comparable approach, we reached a different conclusion. We
analyzed whether TCR transgenic T cells specific for lympho-
cytic choriomeningitis virus gp33–41/Db could inhibit the
priming of endogenous responses against gp33–41 and against
two other lymphocytic choriomeningitis virus glycoprotein-de-
rived CTL epitopes. After priming with different stimuli,
gp33–41/Db-specific TCR transgenic T cells reduced the en-
dogenous gp33–41/Db response in a dose-dependent way, but
all other endogenous responses were unaffected. Even when
>106 TCR transgenic cells were combined with weak priming,
no reduction of responses other than of those specific for gp33–
41/Db was observed. Thus, competition for APC by CTLs of
different specificities is not of functional relevance in antiviral
immune responses. The Journal of Immunology, 2002, 168:
5387–5391.
I n the control of infections with viruses or intracellular bac-teria, CD8 T cells have been shown to be of crucial impor-tance (1). CD8 T cells recognize 8- to 10-aa long peptide
fragments presented on the cell surface by MHC class I molecules
(2). Only a few of the numerous peptides encoded by pathogens
are able to activate specific CD8 T cells, and responses to these
epitopes are often dominated by one or two epitopes. This phe-
nomenon is termed immunodominance (3–5). Knowledge of
mechanisms that influence immunodominance is important to the
understanding of CD8 T cell priming, viral evasion mechanisms,
or the design of vaccines. Several factors that contribute to immu-
nodominance have been identified, and their relative importance
seems to depend on the experimental system used. These include
the efficiency of epitope generation by the Ag-processing machin-
ery, the affinity of the peptide for the presenting MHC class I
molecule, and the abundance of T cells responding to this partic-
ular peptide-MHC class I complex (3, 5–11). Antigenic competi-
tion, in which immune responses to one determinant are inhibited
by simultaneous exposure to (other) Ags on the same APC (im-
munodomination), has recently been suggested to contribute to
immunodominance (5, 12–14). The observation that, upon second-
ary challenge (15–17) or in the memory phase (18) of an immune
response, the affinity of the responding T cells increases without
evidence for affinity maturation of the TCR is also interpreted in
terms of T cell competition. Thus, T cells with a higher affinity
must have an advantage in secondary responses (where usually the
antigenic load is low), suggesting that T cells compete for Ag.
Obviously, in the aforementioned experiments (15–18), competi-
tion is studied between T cells with the same specificities but dif-
ferent TCR affinities.
Whether T cells with different specificities compete with each
other for access to APC has been addressed in three systems with
studies using: 1) C57BL/6-anti-BALB.B minor histocompatibility
Ags (12, 13); 2) H-Y and B6dom1 minor histocompatibility Ags
(19, 20); and 3) OT-1 transgenic T cells (specific for the OVA-
derived peptide SIINFEKL (S8L)/Kb) combined with infection
with recombinant vaccinia virus (VV)4-expressing OVA or prim-
ing by dendritic cells (DC) loaded with antigenic peptides (14). In
the studies using transplantation Ags, elimination of APC by dom-
inant CTL (faster, more) was suggested as a mechanism, whereas
the study using OVA claimed that T cell competition for access to
APC was responsible.
To study whether T cell competition for Ag-bearing APC is a
mechanism of general importance in immunodominance, we adop-
tively transferred titrated numbers of TCR transgenic CD8 cells
(318, specific for lymphocytic choriomeningitis virus (LCMV)
glycoprotein-derived 33–41/Db) together with priming for LCMV-
derived CTL epitopes. LCMV is a potent system for studying im-
munodominance, as a strong and well-characterized CTL response
directed against three LCMV glycoprotein-derived immunodomi-
nant epitopes (gp33–41/Db, gp34–41/Kb, gp276–286/Db) is elic-
ited. To prime different numbers of specific CTL, mice were in-
jected with LCMV, gp1–60 transgenic DC, or VV-G2 (expressing
LCMV glycoprotein). Analysis of the endogenous CTL response
against all immunodominant epitopes showed that no inhibition of
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endogenous CTL response against epitopes other than gp33
occurred.
Materials and Methods
Mice
C57BL/6 mice were obtained from the Institut fu¨r Labortierkunde (Uni-
versity of Zu¨rich, Zu¨rich, Switzerland). B6.PL (Thy1.1) mice were ob-
tained from The Jackson Laboratory (Bar Harbor, ME). Transgenic mice
expressing the LCMV glycoprotein aa 1–60 (H8 mice) have been de-
scribed previously (21), as have the mice expressing the P14 TCR recog-
nizing LCMV gp33–41/H-2Db (318 mice; Ref. 22). For adoptive transfer
experiments, 318  B6.PL (318.PL) mice were used as donors. All mice
were on a C57BL/6 background. Male mice of 6–10 wk of age were used.
Viruses
LCMV-WE was originally obtained from Dr. F. Lehmann-Grube (Univer-
sity of Hamburg, Hamburg, Germany) (23) and was propagated on L929
cells at a low multiplicity of infection. rVV encoding the LCMV glycop-
rotein (VV-G2) was obtained from Dr. D. Bishop (Institute of Virology,
Oxford, U.K.) and was propagated on BSC40 cells (24).
Generation of bone marrow-derived DC
Bone marrow-derived DC were generated from femora of H8 mice as
previously described (25). DC were cultured in the presence of the ago-
nistic anti-CD40 mAb FGK45 (50 g/ml; Ref. 26) during the last 48 h.
Adoptive transfer and infection
318.PL CD8 splenocytes were positively selected on a VS/LS column
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manu-
facturer’s instructions. The selected population contained 95%
CD8Thy1.1 cells. CD8 cells were injected into C57BL/6 mice. After
CD8 transfer, mice were infected with 102 PFU LCMV-WE or with 106
PFU VV-G2. Alternatively, mice were injected immediately after adoptive
transfer with H8 DC. Virus, CD8 cells, and DC were injected in 0.2 ml
balanced salt solution into the tail vein.
Abs, tetramers, and flow cytometry
MHC class I tetramers were produced as previously described (27). PE-
labeled anti-CD90.1 (Thy1.1) (clone HIS51) and FITC-labeled anti-CD8
(clone 53-6.7) were obtained from BD PharMingen (San Diego, CA).
At indicated timepoints, blood samples were stained for 10 min at 37°C
with tetramer, followed by staining with anti-CD8FITC  anti-Thy1.1PE
for 30 min at 4°C. Samples were washed twice, erythrocytes were lysed
with FACS lysis solution (BD Biosciences, Mountain View, CA), and an-
alyzed on a FACScan using CellQuest software (BD Biosciences).
Determining viral titers
LCMV titers were measured in the spleens of infected mice at the indicated
timepoints. Organs were homogenized and monolayers of MC57G cells
were infected with 10-fold dilutions of the homogenate for 48 h. LCMV
was detected by intracellular staining with a monoclonal rat anti-LCMV
nucleoprotein (VL4) as described (28). VV titers were determined in ova-
ries: confluent monolayers of BSC40 cells were infected with 10-fold di-
lutions of the ovary homogenates. Plaques were visualized by crystal violet
after 48 h.
Results
Transferred LCMV gp33-41/Db-specific TCR transgenic (318)
CD8 cells inhibit the endogenous gp33-41/Db response, but
leave other endogenous, LCMV-specific responses intact
Infection of C57BL/6 mice with 100 PFU LCMV-WE primed sub-
stantial numbers of CD8 cells for each of the three LCMV gp-
derived immunodominant epitopes. Mice were bled 12 days after
infection (peak of the response in the blood) and cells were stained
with Cychrome-labeled tetramers, PE-labeled anti-Thy1.1 and
FITC-labeled anti-CD8 Abs. The percentage of endogenous spe-
cific CTL was determined within the CD8Thy1.1 population.
We found that 14.9% of CD8 cells were specific for gp33, 10.4%
for 34, and 3.0% for gp276 (Fig. 1). Adoptive transfer of titrated
numbers of naive MACS-purified CD8 cells from 318.PL mice
that carry a transgenic TCR specific for LCMV gp33 in 50% of
their CD8 cells, together with infection with 100 PFU LCMV-
WE, reduced priming of the endogenous (Thy1.1) CD8 cells for
gp33 in a dose-dependent way (Fig. 1), demonstrating that com-
petition between T cells of the same specificity occurred. The total
number of gp33 CTL (endogenous  transferred) in the spleen 8
days postinfection (p.i.) varied between 3.4–8.9 106 gp33 CTL,
and was relatively independent of the number of adoptively trans-
ferred 318 cells (not shown). This shows that increasing the CTL
precursors does not necessarily increase the response (29, 30). The
competition we observed is well in line with the experiments pub-
lished by Kedl et al. (14) who found that adoptive transfer of TCR
transgenic, SIINFEKL/Kb-specific OT-1 cells inhibited the prim-
ing of SIINFEKL/Kb-specific CD8 cells by VV-OVA. However,
the endogenous response to the other two LCMV glycoprotein-
derived immunodominant epitopes was not affected by adoptive
transfer of 318.PL cells: even after transfer of as many as 106 TCR
transgenic CD8 cells, there was no difference to nontransferred
LCMV-WE-infected mice with respect to the percentage of
CD8Thy1.1 cells specific for gp34 (9.1%) or for gp276 (2.7%),
whereas the endogenous gp33 response was drastically reduced to
0.6% (Fig. 1). We found similar results at days 8 and 30, and also
when we compared blood and spleen (data not shown). In addition,
similar results were obtained after infection of mice with 106 PFU
LCMV-WE (data not shown). Transfer of 318 cells reduced
LCMV loads from days 4 to 5 on; titers in the spleen were similar
in mice that received no cells or 3  104 or 106 TCR transgenic
cells on days 2 and 3 p.i. On day 4 p.i., 3  104 318 cells did not
reduce the titer, but 106 318 cells reduced the titer 2-fold. On day
FIGURE 1. Transferred LCMV gp33-41/Db-specific TCR transgenic
(318) CD8 cells compete against the endogenous gp33-41/Db response,
but not against other endogenous LCMV-specific responses. C57BL/6
mice were adoptively transferred with titrated numbers of 318.PL CD8
cells and were infected with 100 PFU LCMV-WE. Twelve days after in-
fection, PBL were stained with Cychrome-labeled gp33-41Db, gp34-41Kb,
or gp276-286Db tetramers, with anti-CD8-FITC and with anti-Thy1.1-PE
as described in Materials and Methods. Data were analyzed by gating on
CD8 cells; Thy1.1 cells represent the adoptively transferred 318 cells,
whereas Thy1.1 cells represent the endogenous response. The number
given in the lower right quadrant represents the percentage of tetramer-
positive cells of the endogenous response. Representative stainings are
shown.
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5 p.i., 3  104 318 cells reduced titers 2-fold, and 106 318 cells
reduced titers 100-fold.
Adoptively transferred LCMV gp33–41/Db-specific TCR
transgenic CD8 cells do not inhibit priming of endogenous
CD8 responses to other LCMV-derived epitopes, not even
when priming is weak
In the experiments described above, we found no evidence for T
cells that inhibit priming of T cells specific for other epitopes pre-
sented by the same APC. Because infection with LCMV, a non-
cytopathic virus that is known to replicate well in immunocompe-
tent mice, primes a vehement CTL response, we reasoned that
priming with a weaker infectious agent that putatively gives rise to
less LCMV-presenting APC might reveal evidence for T cell com-
petition for access to Ag-bearing APC. Therefore, we transferred
318 CD8 cells into C57BL/6 mice infected with 100 PFU
LCMV-WE or with 106 PFU VV-G2, and measured the endoge-
nous CTL response against all immunodominant LCMV glyco-
protein-derived CTL epitopes expressed by both pathogens 9 days
later (peak response in the blood after VV priming). Infection with
LCMV-WE confirmed the data shown in Fig. 1. As little as 104
318 CD8 cells (equivalent to 5000 gp33-specific cells) already
inhibited the priming of endogenous gp33-specific response to
some extent; considerable (LCMV-WE) to almost complete (VV-
G2) inhibition was observed after transfer of 105 318 CD8 cells.
No inhibitory effect was seen on the priming of the two other
immunodominant specificities, not even after transfer of 106 318
CD8 cells (Fig. 2A). Even after very weak priming with VV-G2
(compare the percentages of tetramer-positive cells of Fig. 2B with
those of Figs. 2A), we found no evidence for inhibition of priming
of the endogenous gp34 or gp276 response, whereas priming of the
endogenous gp33 response was clearly inhibited (Fig. 2B). We
found no evidence for enhanced VV elimination due to transferred
318 cells (up to 106) as measured in the ovaries 5 days after in-
fection. Importantly, tetramer-positive cells of all three specifici-
ties were fully functional independent of the number of transferred
318.PL CD8 cells as determined by chromium-release assay (not
shown).
Transferred LCMV gp33-41/Db-specific TCR transgenic (318)
CD8 cells compete against the endogenous gp33-41/Db
response, but not against the gp34-41/Kb response after priming
with gp1-60 expressing DC (H8 DC)
We primed C57BL/6 mice with titrated numbers of transgenic H8
DC (23) combined with transfer of titrated numbers of 318.PL
CD8 cells. H8 DC continuously present both gp33 and gp34 and
have the advantage over peptide-loaded DC that off-rates of pep-
tides are not confusing the experimental system. Mice were bled at
day 7, at which the peak response after DC priming is seen. We
found that mice injected with 105 H8 DC, together with titrated
numbers of TCR transgenic CD8 cells, displayed a dose-depen-
dent inhibition of priming of endogenous gp33 CTL, but did not
affect priming of gp34 CTL (Fig. 3). Similar results were obtained
if mice were primed with 106 H8 DC (not shown).
Discussion
T cell competition for Ag-expressing APCs has been suggested as
a mechanism that can determine the selective outgrowth of higher
affinity T cells (15–18), but that can also play an important role in
immunodominance. The experiments described in this study were
designed to address the controversial issue of T cell competition
for APC.
The feature of T cell competition has been addressed before,
using different setups. The experimental system used by Perreault
and colleagues (19, 20) is based on adoptively transferring male
C57BL/6 (H-Y and B6dom1), female C57BL/6 (B6dom1), or male
C3H.SW (H-Y) cells into female C3H.SW mice, followed by anal-
ysis of H-Y and B6dom1-specific CTL. B6dom1-specific CTL were
found to inhibit priming of H-Y-specific CTL when both epitopes
were presented by the same APC. B6dom1-specific CTL were
shown to expand more rapidly and eliminate APC before H-Y
specific CTL were primed, resulting in immunodominance of
B6dom1. B6dom1-specific CTL may expand faster, because of more
efficient priming; as was shown in the same study, 800 B6dom1/Db,
and only 8 H-Y/Db, complexes were present on APC. The same
mechanism was suggested to be operative in immunodominance in
the C57BL/6-anti-BALB.B CTL response by Wolpert and col-
leagues (12, 13); they reported that CTL response specific for the
FIGURE 2. Transferred LCMV gp33-41/Db-specific TCR transgenic
(318) CD8 cells compete against the endogenous gp33-41/Db response,
but not against other endogenous LCMV-specific responses, and this is
independent of antigenic load or the degree of priming. Titrated numbers
of 318.PL CD8 cells were adoptively transferred into C57BL/6 mice,
followed by infection with (A) 100 PFU LCMV-WE, or (B) 106 PFU
VV-G2 (expressing LCMV glycoprotein). FACS staining was done as de-
scribed in Fig. 1. Data represent the mean  SD of three individual mice
bled at day 9 after infection. This experiment was performed three times
with similar results.
FIGURE 3. Transferred LCMV gp33-41/Db-specific TCR transgenic
(318) CD8 cells compete against the endogenous gp33-41/Db response,
but not against the gp34-41/Kb response after priming with 105 gp1-60
expressing DC (H8 DC). Titrated numbers of 318.PL CD8 cells were
adoptively transferred together with H8 DC into C57BL/6 recipients.
FACS staining was done as described in Fig. 1. Data represent the mean 
SD of three individual mice bled at day 7 after priming. This experiment
was performed two times with similar results.
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immunodominant epitope (H-28c) developed faster than those spe-
cific for the subdominant epitopes (H-8c, H-19c, and H-25c).
To explain T cell competition, a second hypothesis has been
suggested by Kedl et al. (14). They suggested that “crowding” of
T cells of one specificity on the APC physically inhibited the ac-
cess of other T cells to this APC and, in addition, they excluded
elimination of APC. This hypothesis received considerable atten-
tion recently. Kedl et al. (14) transferred titrated numbers of TCR
transgenic OT-1 cells (specific for OVA-derived S8L) together
with infection with VV-OVA, and analyzed priming of endoge-
nous S8L- and KVVRVDKL (K8L) (a subdominant, Kb-restricted
OVA-derived epitope)-specific CTL. They found that OT-1 cells
inhibited the priming of both endogenous responses. In addition,
they primed mice with peptide-loaded DC (S8L and SIYRYYGL,
the Kb-restricted 2C epitope) together with OT-1 transfer and
found that priming of endogenous SIYRYYGL-specific CTL was
inhibited if S8L was present on the same DC, but not if the two
peptides were on different DC. They interpreted these data such
that large numbers of OT-1 cells interacted with the S8LS-pre-
senting APC, thus inhibiting priming of other CTL. As CTL pre-
cursors usually make up a rather small population in a naive mouse
that is dispersed over several lymphoid organs, it is difficult to
conceive how this crowding should function under physiological
conditions. Therefore, we used a comparable setup to further in-
vestigate the relevance of T cell competition for access to Ag-
expressing APC. We adoptively transferred TCR transgenic 318
cells, together with priming with LCMV, VV-G2, or transgenic H8
DC, and analyzed the endogenous gp33 CTL response, as well as
the response to two additional LCMV glycoprotein-derived
epitopes (gp34 and gp276). We clearly could inhibit the endoge-
nous gp33 CTL response by transfer of as few as 104 318 cells and
completely inhibited the endogenous response by 105 or more 318
cells. This is in agreement with data published by others (14, 31),
and illustrates that there is apparently a limit to the number of
specific T cells that can be primed or that can expand in a host (29,
30, 31). This might be an important mechanism to disconnect pre-
cursor frequency and size of the immune response, thus allowing
a response that is proportional to the antigenic load, as has been
suggested before (29, 31). However, we could not reproduce the
finding that T cells of one specificity inhibited priming of T cells
of other specificities if these Ags were presented by the same APC;
although the different ways of priming we used led to responses of
different magnitude (between 1.5 and 10% tetramer-positive cells
within the CD8 population), we never found inhibition of priming
of the gp34 or of the gp276 response. Thus, in our experiments that
were very similar to those published by Kedl et al. (14), we found
no evidence for the hypothesis that CTL of one specificity can
inhibit priming of CTL for another specificity by hampering access
of the latter to the APC.
A possible explanation for this discrepancy might be that the
OT-1 epitope (S8L) is presumably, due to its higher affinity for Kb,
present in higher numbers on VV-OVA-infected APC than the
subdominant epitope (K8L), resulting in more efficient (more
and/or faster) priming of S8L-specific CTL, which was actually
observed (0.4% S8L- and 0.07% K8L-specific CTL were primed
by VV-OVA (14). As a comparison, VV-G2 primes around 2% for
all three glycoprotein-derived epitopes). Thus, before K8L-specific
CTL were able to interact with sufficient Ag to be substantially
primed, the APC might have been eliminated. Although no effect
of transferred OT-1 cells on VV-OVA clearance was reported (14),
subtle effects on the number of APC, that are not reflected by
reduction of virus titer may be sufficient to reduce the priming of
the subdominant epitope. The discrepancy between the experi-
ments using priming with DC might be explained by the fact that
Kedl et al. used peptide-loaded DC, whereas we used DC that
produce the Ags endogenously. In our study, off-rates from the
presenting MHC class I molecules do not confuse the system, and
in addition, may be more physiological, as infected APC will also
continuously present Ags.
Thus, our data do not support the hypothesis that T cell com-
petition for access to Ag-expressing APC due to crowding (14) is
a phenomenon of functional importance in priming of antiviral
immunity or in immunodominance. However, in some situations T
cell competition has been shown to play a decisive role in immu-
nodominance; in these studies, the mechanism has been shown to
depend on differences in CTL priming and/or expansion as the
major feature, resulting in elimination of APC by immunodomi-
nant CTL before the subdominant CTL could be substantially
primed (12, 13, 19, 20).
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